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Summary Small-cell neuroendocrine carcinoma of the lung is known to express products related to the
vasopressin gene, although these products have been reported to sometimes differ from those generated by
neurones of the hypothalamo-neurohypophyseal system. To further investigate vasopressin gene expression in
neuroendocrine carcinomas, we performed immunohistochemistry on 24 histologically classified small-cell
carcinomas using antibodies directed against different regions of the vasopressin precursor. All of the tumours
examined contained at least two parts of the vasopressin precursor, suggesting that vasopressin might have a
biological role in these tumours and indicating a role for these products in tumour diagnosis and treatment.
Sixty-seven per cent of the tumours contained immunoreactivity for all major regions of the precursor:
vasopressin, vasopressin-associated human neurophysin, the bridging region between the hormone and the
neurophysin, and vasopressin-associated human glycopeptide. However, 33% of the tumours examined
appeared to express only part of the vasopressin precursor, as evidenced by the absence of immunoreactivity
for the neurophysin and/or the glycopeptide. These results support the proposition that both normal and
abnormal vasopressin gene expression occurs in small-cell carcinoma of the lung.
The production of vasopressin (VP) by lung tumours was
suggested over 30 years ago (Schwartz et al., 1957). Since
that time, studies have indicated that the majority of tumours
classified as small-cell carcinoma of the lung (SCCL) express
a VP gene (North et al., 1980a; Memoli & North, 1987;
North, 1991; Gross et al., 1993). This production of
vasopressin-related peptides by neoplastic tissues appears to
differ from that by neurones of the hypothalamo-neuro-
hypophyseal system. The primary products of VP synthesis in
neurones of this system are equimolar amounts of the hor-
mone, an associated neurophysin (VP-HNP) and a glycopep-
tide (VP-HGP). In SCCL however, Yamaji et al. (1984)
found that the predominant secretory product in one neo-
plastic cell line was the precursor molecule, provasopressin
(proVP), while North (1991) reported on patients diagnosed
with SCCL who had elevated levels of either VP or VP-HNP,
but not both substances. Perhaps the strongest evidence for
altered neoplastic production is the demonstration of larger
forms of neurophysin-immunoreactive proteins in SCCL cell
lines and tumour extracts and the presence of novel forms of
VP-mRNA in tumour cell lines (North et al., 1983; Rosen-
baum et al., 1990; North & Yu, 1993).
In this study, we describe the development of antibodies
directed against an octadecapeptide representing the C-
terminal sequence of VP-HGP. These antibodies, along with
those against VP, VP-HNP and a dodecapeptide that
includes the tripeptide bridging structure ofproVP, were used
in immunohistochemistry to examine expression of the VP
gene in a library of 24 SCCL tumours.
Materials and methods
Tumour specimens
Paraffin-embedded surgical specimens were obtained from a
library of SCCL tumours at Dartmouth Hitchcock Medical
Center. The specimens were fixed in acetone within 90 min of
tumour resection and processed according to the AMeX
(acetone, methylbenzoate, xylene) method (Sato et al., 1986).
Diagnosis for SCCL was confirmed at the light microscopic
level on haematoxylin and eosin-stained sections according to
the WHO classification. Moreover, neuroendocrine differenti-
ation was demonstrated by electron microscopy and/or
immunohistochemical detection of known markers of
neuroendocrine phenotype. Of the 24 SCCL tumours
selected, eight were removed from the lung, while 16 were
biopsies of metastases to either the lymph nodes or other
organs. For immunohistochemistry, paraffin-embedded sec-
tions of 4 gm were transferred to microscope slides.
Antibodies
The preparation and specificity of rabbit polyclonal
antibodies directed against VP (Gonzo-3) and a mouse
monoclonal antibody to VP-HNP (NAbl) have been de-
scribed in previous publications (North & Yu, 1993; North et
al., 1993). The specificity of NAbl was further improved by
purification on an affinity column of VP-HNP bound to
Sepharose using the method of North et al. (1989). The
rabbit polyclonal antibody preparation (YL-3) that recog-
nises the tripeptide bridge connecting VP with VP-HNP in
the vasopressin precursor (proVP) was a generous gift from
J. Verbalis (Pittsburgh, PA, USA) and has been characterised
by others (Rosenbaum et al., 1990).
Since antibodies against VP-HGP were not available, these
were developed for the present study following a method
described in an earlier publication (North et al., 1980b). A
synthetic peptide having the sequence corresponding to the
C-terminal 18 amino acid residues of VP-HGP (HGP22 39)
(Mimotopes, Australia) was used as the antigen in this proce-
dure and a New Zealand strain rabbit served as the host.
Blood was collected 4 weeks after a second boost injection,
and the serum (Boris Y-2) was used in immunohistochemis-
try. Using '25I-labelled HGP22-39, these antibodies demon-
strated a capacity to bind 50% of radiolabelled peptide
(pH 7.5) at a serum dilution of 1:800.
Immunohistochemistry
Four-micron sections from each tumour specimen were
deparaffinised and stained using the Vectastain Elite
avidin-biotin complex (ABC) immunohistochemical protocol
(Vector Laboratories, Burlingame, CA, USA). Antibodies
were diluted with 10% normal serum and incubations carried
out at the following concentrations: YL-3 (bridging region of
proVP), serum dilution 1:200-1:600; Gonzo-3 (VP), serum
dilution 1:200-1:400; NAbl (VP-HNP), 0.05-0.025 jigml-'
purified IgG; Boris Y-2 (VP-HGP), serum dilution
1:600-1:1,000. Optimal staining for each specimen was
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obtained by using these antibody concentrations and by
varying the time of incubation with primary antibody
between 2 and 48 h. Two hour incubations were carried out
at room temperature, while longer incubations were carried
out at 4°C. Prior to addition of ABC reagent, the activity of
endogenous peroxidase was blocked by immersing tissue sec-
tions for 20 min at room temperature in 3% hydrogen perox-
ide dissolved in absolute methanol (Streefkerk, 1972).
Visualisation was achieved by adding 3,3'-diaminobenzidine
(0.2 mg ml-' dissolved in phosphate-buffered saline and
0.03% hydrogen peroxide) for 2min. The slides were then
counterstained with haematoxylin, dehydrated and coverslip-
ped.
Sections were examined by light microscopy using an
Olympus BH2-BHYU microscope, and photographed using a
Leitz Ortholux II microscope equipped with a Leitz Vario-
Orthomat camera system. The specificity of the antibodies in
immunohistochemistry was demonstrated by the positive
identification of neuronal cell bodies and axon terminals in
paraffin-embedded sections of human hypothalamus and
posterior pituitary, and by a lack of staining in sections
incubated with normal serum in place of primary antibody.
Results
Vasopressin andprovasopressin immunoreactivity
Immunoreactivities for the different parts of the VP precur-
sor in 24 SCCL tumours are summarised in Table I. All
tumours examined (24 of 24) contained immunoreactivity for
both VP and the bridging region of proVP. Staining was
located throughout the tumour (Figure la and b) and was
not observed in sections incubated with normal serum in-
stead of primary antibody.
Vasopressin-associated human neurophysin andglycopeptide
Both VP-HNP and VP-HGP immmunoreactivities were
detected in 16 of the 24 SCCL tumours immunoreactive for
VP and the bridging region of proVP (Table I) (Figures 2
and 3). Of the remaining eight tumours immunopositive for
VP and the bridging region of proVP, one did not stain for
either VP-HNP or VP-HGP, three contained immmunoreac-
tivity for VP-HNP in the absence of VP-HGP and four
contained immunoreactivity for VP-HGP in the absence of
VP-HNP. The specificity of antibodies to VP-HGP (Boris
Y-2) was demonstrated by the positive identification of
neurones in the hypothalamus and axonal endings in the
posterior pituitary that also stained for VP-HNP.
Discussion
The present immunohistochemical study demonstrates
immunoreactivity for both VP and the bridging section of
proVP in all 24 SCCL tumours examined, suggesting that
exon A of the VP gene is expressed by all of these tumours.
In contrast, other studies have indicated that between 55%
a
b
Figure 1 a, Positive staining for the bridging region of proVP in
a lymph node metastasis of a SCCL tumour employing YL-3
rabbit polyclonal antibodies and the ABC immunohistochemical
technique. b, VP immmunoreactivity in the same region of this
tumour detected using Gonzo-3 rabbit polyclonal antibodies
(magnification = 516 x).
and 82% of all SCCL tumours express the gene for VP
(North et al., 1980a, 1988; Memoli & North, 1987; North,
1991; Gross et al., 1993). These differences might be
explained by methodological differences, since in this study
tumours were optimally prepared for immunohistochemical
studies and were well characterised for the neuroendocrine
phenotype. The high expression of VP gene expression and
its relative specificity for SCCL underlies the relevance of
employing it as a tumour marker for SCCL, in both diag-
nosis and imaging (North et al., 1988, 1989; North,
1991).
The results of the present study, as well as those of others,
suggesting that the majority of SCCL tumours synthesise the
antidiuretic hormone, are in apparent contrast with the
clinical observation that only 20-40% of patients diagnosed
with SCCL show symptoms of the syndrome of inapprop-
Table I Immunoreactivity for VP, VP-HNP and VP-HGP and the
bridging region of proVP, in tumour specimens from 24 cases of
SCCL
Percentage
Cases of total ProVP VP VP-HNP VP-HGP
n =16 67 + + + +
n=l 4 + + - -
n=4 17 + + - +
n=3 12 + + +
Pluses indicate positive staining, while minuses reflect an inability to
detect immunoreactivity for either VP-HNP (column 4) or VP-HGP
(column 5).
261262 A.S. FRIEDMANN et al.
p M
Figure 2 Staining for VP-HNP (arrows) in SCCL cells of a
lymph node metastasis using the mouse monoclonal antibody
NAbl with the ABC technique. Unlike cells of the tumour
depicted in Figure 1, the majority ofcells in this tumour were not
immunoreactive for VP gene products, illustrating the
heterogeneity of SCCL tumours with regard to VP production
(magnification = 812 x).
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bit polyclonal antibodies (Boris Y-2) and the ABC technique in
an SCCL tumour that metastasised to the spinal cord. This
tumour also displayed immunoreactivity for VP, VP-HNP and
the bridging region of proVP (magnification = 812 x).
riate ADH (SIADH) (Moses & Scheinman, 1991). This dis-
parity indicates that VP-producing tumours are hetero-
geneous with regard to hormone secretion, with only a
selected number of these tumours secreting amounts of VP
sufficient to produce the paraneoplastic syndrome. Addi-
tionally, North (1991) has suggested that factors in addition
to the level of VP secretion are responsible for SIADH.
Examination of SCCL tumours with antibodies directed
against VP-HNP and VP-HGP allows for some comparisons
to be made between VP production in the neoplastic cells
and that in hypothalamic neurones. Immunoreactivity for
VP-HNP and VP-HGP was observed in 16 out of the 24
tumours that were also immunoreactive for VP and the
bridging region of proVP. This observation suggests that the
synthesis of VP by these neoplastic cells resembles that by
hypothalamic neurones, in that the precursor molecule con-
tains all four of the principal moieties (vasopressin, bridging
peptide, neurophysin and glycopeptide). In contrast, some
tumours demonstrate immmunoreactivity for VP and the
bridging region of proVP in the absence of any detectable
VP-HNP and/or VP-HGP. In agreement with these immuno-
histochemical findings. North (1991) has reported disparities
between levels of VP and VP-HNP in the plasma of patients
diagnosed with SCCL. It is possible, then, that some of these
tumours produce a precursor different from that found in the
hypothalamus. Alternatively, the presence of VP without its
associated neurophysin or glycopeptide might be due to the
existence of differing rates of secretion or degradation for the
hormone and the neurophysin. Nevertheless, these findings
further demonstrate a heterogeneity of SCCL tumours with
regard to their expression of the VP gene.
Western blot analysis has revealed a heterogeneous popula-
tion of peptides in SCCL tumours and cell lines that are
immunoreactive for VP-HNP, some of the same molecular
size as hypothalamic proVP and others that are larger (North
et al., 1983; Rosenbaum et al., 1990; North & Yu, 1993).
Immunohistochemical and biochemical studies on three
different cell lines indicate that this neurophysin immunoreac-
tivity is closely associated with the plasma membrane (North
et al., 1983; Rosenbaum et al., 1990). The basis for this
heterogeneity might be in the structure of the VP mRNA.
Examination of VP gene transcripts in SCCL cell lines, em-
ploying Northern blot analysis and the polymerase chain
reaction (PCR), suggests the existence of both a VP mRNA
that is similar or identical to that in the hypothalamus
(Verbeeck et al. 1992; North & Yu, 1993) and a larger
form(s) that appears to exhibit differences at the 3' end
representing exons B and/or C of the VP gene (Rosenbaum
et al., 1990; Verbeeck et al., 1992; North & Yu, 1993). In the
two SCCL cell lines examined by North & Yu (1993), the
novel form of VP mRNA was the predominant one. This
observation might explain the inability of others to detect VP
mRNA in SCCL cell lines (Verbeeck et al., 1992) at the same
high frequency as we and others find for the protein products
(Memoli & North, 1987; North et al., 1988; North, 1991;
Gross et al., 1993).
Whether or not normal cells in the lung produce VP is
currently unknown, although the expression of the VP gene
has been demonstrated in a growing number of extra-
hypothalamic sites. That one of these sites might be the lung
is raised by Almenoff et al. (1993), who have found levels of
immunoreactive VP in the normal rat lung that are above
those in the circulation.
The current demonstration of VP gene products in all 24
SCCL tumours examined adds to the growing body of
evidence that there is a high incidence of expression of this
gene in SCCL tumours. Our findings support those of others
that suggest the heterogeneous nature of this synthesis. The
finding of VP immunoreactivity in all the tumours examined,
taken together with the reported effects of VP on SCCL
growth, suggests the peptide plays an important role in
tumour physiology. The lack of complete coincidence
between staining for VP, VP-HNP and VP-HGP suggests
that a combination of these antibodies against the various
VP gene products could be effective for imaging all SCCL
tumours.
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